SecBot SecBot
PRESS-RELEASE ·Filed May 12, 2026

SLDB

Solid Biosciences Inc.
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The EPS miss and widening losses are negative, but the strong cash position and Phase 3 Duchenne trial progress provide a floor. Watch for FDA guidance on accelerated approval for SGT-003 and initial FALCON data by year-end 2026 as potential catalysts.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$7.38
T+0 close · May 12, 2026 · via day close
Latest settled
+13.69%
T+60 · $8.39
Vs SPY
+9.25%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $7.38entry
  2. T+1 · 6mo ago 0.00%α +0.00% · $7.38
  3. T+5 · 6mo ago −17.62%α −16.46% · $6.08
  4. T+20 · 5mo ago −2.17%α −1.56% · $7.22
  5. T+60 · 3mo ago +13.69%α +9.25% · $8.39
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Solid Biosciences reported Q1 2026 EPS of -$0.53, a 20.9% miss versus the -$0.44 consensus, with net loss widening to $56.7M from $39.3M a year ago. The company highlighted Phase 3 Duchenne trial initiation and a strong cash position of $380.7M extending into H1 2028, but the earnings miss and rising R&D costs overshadow pipeline progress.

Key Financial Metrics

EPS
−$0.53
est −$0.44 · -20.4%
Rating
miss

Key Facts

  • Q1 2026 EPS of -$0.53 missed consensus of -$0.44 by 20.9%
  • Net loss widened to $56.7M from $39.3M in Q1 2025
  • Cash, cash equivalents and securities totaled $380.7M as of March 31, 2026, up from $187.9M at year-end 2025
  • R&D expenses rose to $46.1M from $30.9M, driven by SGT-003 manufacturing and clinical costs
  • First participant dosed in Phase 3 IMPACT DUCHENNE trial for SGT-003
  • 47 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial as of May 11, 2026
  • Two participants dosed in Phase 1b FALCON trial for Friedreich's ataxia; no serious adverse events
  • Cash runway expected into H1 2028

Financial Impact

EPS miss of 20.9% vs consensus; net loss increased 44.4% YoY to $56.7M

epsnet lossr&d expenses

Risk Factors

  • Continued cash burn with no near-term revenue; R&D costs may rise further
  • Regulatory setbacks or delays in SGT-003 accelerated approval pathway
  • Competition from other Duchenne gene therapies (e.g., Pfizer, Sarepta)

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3293411

Track record

14 reports on SLDB

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +20.77% at T+20 after the Mar 19, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $6.84 Now $6.48 −5.26% settles Dec 15
  2. Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $7.02 Now $6.48 −7.69% settles Dec 8
  3. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $6.18 Now $6.48 +4.85% settles Dec 4
  4. Aug 6, 202614w ago S-3ASR Neutral 4/10 Entry $8.39 to $10.25 Now $6.48 −22.77% ▲ +22.17% +22.57% vs SPY
  5. May 12, 202626w ago Press Release Bearish 6/10 Viewing Entry $7.38 to $7.22 Now $6.48 +12.20% ▲ +2.17% +1.56% vs SPY
  6. May 7, 202627w ago Press Release Bullish 7/10 Entry $7.07 to $6.85 Now $6.48 −8.35% ▼ −3.11% −6.25% vs SPY
  7. Apr 23, 202629w ago DEFA14A Neutral 3/10 Entry $7.92 to $6.50 Now $6.48 −18.18% ▼ −17.93% −21.96% vs SPY
  8. Apr 10, 202631w ago 8-K Neutral 2/10 Entry $8.39 to $7.68 Now $6.48 −22.77% ▼ −8.46% −16.19% vs SPY
  9. Apr 1, 202632w ago EFFECT Bearish 7/10 Entry $7.38 to $7.05 Now $6.48 +12.20% ▲ +4.47% +14.19% vs SPY
  10. Mar 19, 202634w ago Press Release Bullish 8/10 Entry $7.03 to $8.49 Now $6.48 −7.82% ▲ +20.77% +11.45% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026